Reviewed by a Canadian pharmacist
A recent review that examined the efficacy, safety, and perspective for the future of the once-weekly GLP-1 receptor agonists exenatide, taspoglutide, albiglutide, LY2189265 and CJC-1134-PC, and compared them to the currently available agonists, exenatide BID and liraglutide QD, concluded that the long-acting agonists are not superior compared to the currently used exenatide BID and liraglutide QD regarding weight loss (127).In a separate development, an orally administered PYY3-36 and GLP-1 combination has been formulated using a sodium N-[8-(2-hydroxybenzoyl) amino] caprylate (SNAC) carrier (127)
[DOI] [PubMed] [Google Scholar] 170.Gth L., Rass P., Madarasi I
Furthermore, it increased the frequency of Treg cells and levels of TGF-, while inhibiting the activation of Tfh and Th17 cells as well as the production of IL-21